Author:
Oteri Giacomo,Trifirò Gianluca,Peditto Matteo,Lo Presti Loredana,Marcianò Ilaria,Giorgianni Francesco,Sultana Janet,Marcianò Antonia
Funder
Agenzia Italiana del Farmaco, Ministero della Salute (IT)
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference51 articles.
1. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Min Res. 2008;23(6):826–36.
2. Fusco V, Porta C, Saia G, et al. A osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an italian multicenter study and review of the literature. Clin Genitourin Cancer. 2015;13(4):287–94.
3. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. American Association of Oral and Maxillofacial Surgeons. J Oral Maxillofac Surg. 2014;72(10):1938–56.
4. Voss PJ, Joshi Oshero J, Kovalova-Müller A, et al. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniomaxillofac Surg. 2012;40(8):719–25.
5. Stockmann P, Burger M, von Wilmowsky C, et al. The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw—results of a clinical case series with an average follow-up of 20 months. Clin Oral Investig. 2014;18(4):1299–304.